Drugs / IL-13-PE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01832974 | Dec 2012 → Mar 2014 | adrenal cortex carcinoma | INSYS Therapeutics Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-13-PE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01832974 ↗ |
| Route | Intravenous | “IL-13-PE intravenous infusion” NCT01832974 ↗ |